Suven Pharmaceuticals is currently trading at Rs. 699.40, up by 32.15 points or 4.82% from its previous closing of Rs. 667.25 on the BSE.
The scrip opened at Rs. 697.35 and has touched a high and low of Rs. 705.00 and Rs. 686.10 respectively. So far 3313 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.00 on 04-Jan-2024 and a 52 week low of Rs. 427.05 on 27-Jun-2023.
Last one week high and low of the scrip stood at Rs. 705.00 and Rs. 638.00 respectively. The current market cap of the company is Rs. 16985.85 crore.
The promoters holding in the company stood at 50.10%, while Institutions and Non-Institutions held 26.79% and 23.10% respectively.
Suven Pharmaceuticals has executed definitive agreements on June 13, 2024, for acquiring 100% of equity shares (on a fully diluted basis) in Sapala Organics. Sapala Organics is a Hyderabad based CDMO focused on Oligo drugs and nucleic acid building blocks including Phosphoramidites & Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others.
The company has agreed to initially acquire 67.5% by way of secondary transfer from Sapala Organics’ existing shareholders. This represents 51% of the share capital of Sapala Organics on a fully diluted basis. After financial year 2026-27, the company will acquire the balance shareholding through secondary purchase, such that, post consummation, the company will own 100% of the share capital of Sapala Organics on a fully diluted basis.
Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.50 |
| Dr. Reddys Lab | 1342.45 |
| Cipla | 1472.45 |
| Lupin | 2147.55 |
| Zydus Lifesciences | 973.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
